Select Page ::

Tesla Driver Loses Control, Hits and Critically Injures Teen Girl in Long Beach – NBC Southern California

Posted on January 19, 2020 by Danzig

A teenager was injured and in critical condition after a Tesla driver appeared to lose control of her vehicle and strike the pedestrian before crashing at a gas station Saturday in Long Beach, police said.

The crash occurred around 11:25 a.m. near the intersection of Alamitos Avenue and East Broadway, according to the Long Beach Police Department.

The driver of the Tesla lost control of her vehicle and hit the teenage girl, who was taken to the hospital in critical condition, the LBPD said. Witnesses said that the woman had just had her car detailed at a shop across the street, police said.

Local news from across Southern California

The car went through a flower bed, hit the teenager and then crashed into another car at a gas station, Long Beach police said.

The driver was also taken to the hospital in stable condition, police said.

Impairment did not appear to be a factor and it was not immediately clear what caused the incident, police said.

Go here to see the original:

Tesla Driver Loses Control, Hits and Critically Injures Teen Girl in Long Beach - NBC Southern California

Why Tesla [TSLA] Is On A Tear No Other Auto Company In The World Thats Growing That Quickly. – CleanTechnica

Posted on January 19, 2020 by Danzig

Cars

Published on January 14th, 2020 | by Johnna Crider

January 14th, 2020 by Johnna Crider

Tesla is growing like no other company in the auto industry and is pretty much on a tear. This is a good thing.In late 2019, as in four days before 2020, CNBC had Steve Westly, a former Tesla board member and a member of the Westly Group, on its Power Lunch show. They got right to the point with this question: Whats changed in 90 days?

Westley says that it is the numbers and breaks it down into four points:

1. Tesla is showing strong growth. Tesla delivered 245,000 cars in 2018 and between 360,000 and 370,000 in 2019. Theres no other auto company in the world thats growing that quickly.

2. Strong international growth in both Europe and China. In China, Tesla built the Gigafactory 3 in 11 months and is delivering vehicles today already.

3. Tesla is bringing new products to the market all the time. The Model Y will be coming out this summer, Westley says, ahead of plan. The Model Y will be followed by the Tesla Semi and the Cybertruck. Tesla is bringing products to the market faster than anyone else. (Editors note: That claim isnt exactly correct. Some other automakers are rolling out more new BEV models in the coming year. However, perhaps if you assume a reference to mass-market models this is correct. Perhaps.)

4. Tesla is profitable. It was profitable in Q2 and Q3 of 2019. Westly said he thinks that it will be profitable in Q4. Note that just a few months ago many critics said that Tesla was never going to be profitable.

The simple fact is he knows how to create great products and hes bringing them to market faster than anyone else. Steve Westly on Elon Musk

Elon Musk was brought up as a fifth reason that Tesla is doing so great. One of the hosts said that people invested in Elon and when he misbehaved on Twitter and got himself into trouble the stock started not doing so well, but when he started behaving it seemed to do better. Westly replied by saying that Elon Musk is a lot like Steve Jobs and Thomas Edison they never played by the rules.

Westly predicts that for the next 1218 months Tesla is looking pretty strong.

Follow CleanTechnica on Google News.It will make you happy & help you live in peace for the rest of your life.

Tags: Steve Westly, Tesla, Tesla financials, Tesla Model 3, Tesla Model Y, Tesla profit, Tesla sales, Tesla stock

Johnna Crider Johnna Crider is a Baton Rouge artist, gem and mineral collector, and Tesla shareholder who believes in Elon Musk and Tesla. Elon Musk advised her in 2018 to Believe in Good.Tesla is one of many good things to believe in. You can find Johnna on Twitter

See the rest here:

Why Tesla [TSLA] Is On A Tear No Other Auto Company In The World Thats Growing That Quickly. - CleanTechnica

Tesla & EV Fans: The Perfect Reason You Should Be ‘Going To Miami’ – InsideEVs

Posted on January 19, 2020 by Danzig

EDITOR'S NOTE:This article comes to us courtesy ofEVANNEX, which makes and sells aftermarket Tesla accessories. The opinions expressed therein are not necessarily our own at InsideEVs, nor have we been paid byEVANNEXto publish these articles. We find the company's perspective as an aftermarket supplier of Tesla accessories interesting and are happy to share its content free of charge. Enjoy!

Posted onJanuary 18, 2020byMatt Pressman

Anticipation is growing for the largest Tesla and EV-related eventeveron the East Coast.By reinventing the "Cars and Coffee" meet-ups popular across the country, Miami will play host to the first-everEVs and Teagathering.InsideEVs,MyEV.com, andEVANNEXhave joined forcesto bring something new, big, and excitingto electric car enthusiasts and owners.

EVs and Teais also proud to have non-profit groupPlug In Americaas a partner on the event.It will be heldwithin Miamis hottest new green event space,BASECAMP, featuring one of themost spectacular Tesla car showseverpresentedbySignature Custom Wraps a Ft. Lauderdale shopfamous for restyling and modding carswithin the Tesla community.

BASECAMP's stunning design was partiallyinspired by the Burning Man Festival. The Miami venue is located inside theMagic City Innovation Districtin Little Haiti. There'll befood trucks from world-renowned chefs like Todd English, a juice and alcohol bar, 'Gramophone' DJ stage, Bedouin-themed tent, and interactive art installations.And one art project beingunveiled at the event has everyone buzzing a large-scale Cybertruck model.

This one-of-a-kindCybertruck model has been quietly underwraps atEVANNEXand should provideattendees with a good feel for Tesla's controversial and disruptive truck. In addition to their Cybertruck display,attendees can participate ina special raffle, check out newTesla accessories, and receive gift bags at the event.

Panels and meet-and-greets withhigh-profile members of the Tesla community are scheduled as well. Driving down from Canada, Trevor Page fromTesla Owners Onlinewill be a guest star for thethird year in a row except on a far bigger stage this year.With Trevor's activeforum, almost60,000 subscribers onYouTubeandover50,000 followers onTwitter word is spreading quickly aboutEVs and Teaallover the world.

Other YouTube personalities will also be in attendance including Kyle Connor (Out of Spec Motoring), Michael Bodner (Teslatunity), and Rafael Santoni (TesLatino).SantonirunsTesla Club South Floridawhich is lending its support. Also, special thanks to Larry Chanin ofTesla Club Florida(and all the club's members) who'll be integralto thisexcitinginaugural event.

Others are flying in for the event.Anuarbek Imanbaev, known for his contribution inhelping to bring Tesla to Kazakstananda host of theTesla Geekspodcast, will be flying in from Austin.The otherhost of Tesla Geeks,Eli Burton, will be flying infrom Sacramento. Burton is also President ofMy Tesla Adventureand creator of theAdventures of Starmancomic book series. In addition, attendees will have an opportunity to meet thereal-life Starmandressed up in his signature spacesuit!

Another Californian we'rethrilled to welcome to Miami isMarty Morisse, President ofTesla Club-SoCalandfamous for her Tesla-inspired music video. In addition, we're proud that Tesla will officially beattendingand showcasingtheir complete vehicle line-up.Other automakersare alsoplanning to attend includingAudi (with its e-tron), Jaguar (with its I-PACE), Chevrolet (with its Bolt), and Nissan (with its LEAF). Some othersurprisesare expected as well.

To learn more and RSVP, be sure to visit:evsandtea.com.

Read the original:

Tesla & EV Fans: The Perfect Reason You Should Be 'Going To Miami' - InsideEVs

Bulls And Bears Of The Week: IBM, Microsoft, Tesla And More – Yahoo Finance

Posted on January 19, 2020 by Danzig

Benzinga has examined the prospects for many investor favorite stocks over the past week.

Bullish calls included a software leader and a discount airline.

Bearish calls included an electric vehicle giant and a cult food stock.

The major U.S. indexes end last week with marginal gains again, led by the Nasdaq's nearly 2% increase. A new earnings season kicked off with mixed results from the big banks, and the week saw the phase-one trade deal with China signed as well. Also, the next phase of presidential impeachment process has begun.

Benzinga continues to examine the prospects for many of the stocks most popular with investors. The followingare just a few of this past week's most bullish and bearish posts that are worth another look.

Several large options traders were mostly bullish on Microsoft Corporation (NASDAQ: MSFT) this past week, according to Wayne Duggan's "Microsoft Sees Bullish Option Activity As Stock Hits New All-Time High." How much more upside is there?

"Morgan Stanley Names Occidental Petroleum A Top Pick For 2020" by Priya Nigam points out that Occidental Petroleum Corporation (NYSE: OXY) could maintain a best-in-class dividend yield, among other things.

Tyree Gorges's "5 Reasons To Invest In Spirit Airlines Stock" takes a look at why two analysts are so bullish on ultra-low-cost carrier Spirit Airlines Incorporated (NYSE: SAVE) ahead of its fourth-quarter report,due in early February.

In Shanthi Rexaline's "Wells Fargo Sees 30% Upside In Pinterest Shares, Says 'Fundamentals Remain On Solid Footing'," see some ongoing catalysts for Pinterest Inc (NYSE: PINS).

For additional bullish calls, also have a look at "Pro Investor Says Luckin Coffee More Than Just A Popular Coffee Brand" and "Cord Cutters Haven't Killed The Cable Industry It's Bringing Them Their Broadband."

Bears

In "Tesla B Valuation: Does A Great Product Equate To A Great Stock?" Tom Meilleur asks whether Tesla Inc (NASDAQ: TSLA) has such a strong competitive advantage as to merit its valuation premium.

Priya Nigam's "Morgan Stanley Downgrades IBM, Says Revenue Growth Slowing" discusses why even with synergies from the Red Hat acquisition, long-term revenue growth at IBM (NYSE: IBM) is now less likely.

"Wells Fargo Analyst Says Beyond Meat's Stock Has Downside To " by Jayson Derrick examines why Beyond Meat Inc (NYSE: BYND) shares could retreat more than 30%, according to one top analyst.

NVIDIA Corporation (NASDAQ: NVDA) is not a compelling buying opportunity. So says "Nvidia Analyst Says Chipmaker Lacks Earnings Potential To Justify Lofty Valuation" by Shanthi Rexaline.

Be sure to check out "Boeing's 737 Max Crisis Could Impact US GDP Growth In 2020: Mnuchin" and "UBS Swipes Left On Match, Finds Valuation Unattractive" for additional bearish calls.

At the time of this writing, the author had no position in the mentioned equities.

Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.

See more from Benzinga

See the article here:

Bulls And Bears Of The Week: IBM, Microsoft, Tesla And More - Yahoo Finance

Bitcoin fans just turned their Tesla car into a full node – The Next Web

Posted on January 19, 2020 by Danzig

Tesla cars are capable of a lot,from self-driving, smart summoning, and automatic parking but what about running Bitcoin?

As it turns out, they can do that too. Cryptocurrency fans have shared video footage of a Tesla cars onboard computer system operating as a Bitcoin BTC full node.

[Read:Accidental Tesla butt dial upgrade highlights confusing future of car maintenance]

This is possible thanks to theBcoin project, which shared the video. Bcoin is analternative implementation of the Bitcoin protocol thatany machine like Teslas onboard computer can run via its internet browser to join in the consensus process.

So, for at least a short while, there was aTesla car out there helping to keep Bitcoin chugging along smoothly.

While this is a pretty cool (albeit novel) way to show off theBcoin project, turning your Tesla car into a mobile Bitcoin full node might not be the greatest idea.

Indeed, running a Bitcoin full node is relatively resource intensive, so the processing power required to download and process Bitcoin block data could impact the UX experience of its onboard computer as one Twitter user pointed out.

They also highlighted lifespan issues suffered by memory modules in Tesla cars. Bitcoin full nodes must interact with data quite regularly, which could exacerbate those concerns.

Bcoin devsapparently know this, too. Its website comes complete with a disclaimer. It reads: Warning: this will use a lot of your bandwidth, [CPU], and potentially disk space.

This means its likely thatBcoin devs didnt actually run their full node for very long, and its probably advisable that you do the same, for the sake of your Tesla.

Bitcoin fans have turned other gadgets (albeit smaller ones) into Bitcoin full nodes in the past. Most notably, theyve found the single board computers Raspberry Pito be a particularly good machine for syncing the blockchain.

Published January 17, 2020 15:34 UTC

Follow this link:

Bitcoin fans just turned their Tesla car into a full node - The Next Web

Tesla stock could hit $6,000 per share in the next five years, analyst says – Yahoo Finance

Posted on January 19, 2020 by Danzig

The firm that once predicted Tesla (TSLA) shares would cross the $4,000 mark delivered a new, even more bullish price target for the electric-vehicle maker.

Shares of Tesla could be worth $6,000 each in the next five years, Ark Investment Management analyst Tasha Keeney told Yahoo Finances The Final Round Wednesday.

The soaring target implies a return of more than 1,000% from Teslas closing prices Wednesday. At $6,000 per share, Teslas market capitalization would leap well above the $1 trillion mark, based on shares outstanding as of its latest quarterly earnings update. Teslas current market capitalization is north of $90 billion, or more than that of Ford (F) and GM (GM) combined.

The $6,000 per-share level is Arks bull case scenario, implying a best-case situation for Tesla over the next few years.

Thats assuming our bull case assumptions for the EV (electric vehicle) market, Keeney said. Broadly whats changed in our assumptions over the past few years is, weve always said that Tesla was three years ahead on batteries, autonomous hardware and autonomous data collection. And really were adding software to that, over-the-air software updates.

What weve seen happen is really the rest of the auto market, shockingly, is really so far behind Tesla, she added. I mean there hasnt been an EV produced thats on par with the Model S which came out, you know 7-8 years ago. And so were just seeing it move further ahead on all of those fronts.

Arks investment thesis mirrors that of some other traditional firms on Wall Street, which have recently pointed to Teslas troves of collected data as a launching point for future developments in autonomy.

Oppenheimer analyst Colin Rusch on Monday raised his price target on Tesla to $612 from $385, citing in part Teslas 600,000 cars on the road collecting data from all of their sensor suites helping the company redesign their autonomous system.

The average 12-month price target on Teslas stock is $354.26, according to Bloomberg-compiled data on 30 firms delivering price targets over the past three months, not including Arks call. Shares of Tesla closed at $518.50 each on Wednesday.

Keeney noted that Ark Invest will be publishing an updated model and Tesla price target in the next few weeks.

Tesla Inc CEO Elon Musk takes off his coat onstage during a delivery event for Tesla China-made Model 3 cars in Shanghai, China January 7, 2020. REUTERS/Aly Song

In the past month alone, Teslas stock jumped nearly 50% as deliveries came online from its Shanghai Gigafactory, Chinas first wholly owned car factory by a U.S. automaker.

That factory handed over its first vehicles to public customers within a year of breaking ground in Shanghai in January 2018, bringing Tesla to the worlds largest auto market at a much faster than expected pace.

We think this is just going to accelerate that story, Keeney said. Its going to help the cost structure, its going to help Tesla scale in a capital-efficient matter.

And in the U.S., Keeney said she didnt think a future where Tesla was the No. 1 domestic automaker would be such a wild assumption, especially in the autonomous car space where its a winner-takes-most market.

We think theyre going to be able to launch an autonomous taxi service in the next few years. I think their opportunity could just run away with them, Keene said. And if you look at the other US automakers, I mean again their EV platforms arent as great and theyre really behind on the data collection that you need to get an autonomous platform off the ground.

Emily McCormick is a reporter for Yahoo Finance.Follow her on Twitter: @emily_mcck

Why BlackRock May Pump Teslas Stock to the Moon – CCN.com

Posted on January 19, 2020 by Danzig

Tesla (NASDAQ: TSLA) stock has been on a historic tear. The EV manufacturers market-cap is almost at $100 billion, and it is basking in the warm glow of strong growth prospects and risk-on trading conditions in the U.S. stock market.

Things could still get even better for Elon Musk. The worlds largest asset manager, BlackRock, announced a shift towards sustainable investments. And TSLA might just be the firms new crown jewel.

BlackRock manages an eye-watering $7 trillion fortune and oversees a portfolio that is heavily invested in fossil fuels. Thats about to change.

In his 2020 CEO letter, BlackRock chief executive Larry Fink announced the climate crisis as the catalyst for the stock market behemoths planned re-allocation, stating,

We will see changes in capital allocation more quickly than we see changes to the climate itself. In the near future and sooner than most anticipate there will be a significant reallocation of capital.

He was careful not to state there was going to be a total divestment from oil companies. This would be very impractical from a liquidity standpoint. BlackRock invests more in fossil-fuel reserves than anyone else in the world.

This commitment to green investing, suddenly leaves Tesla front and center as the perfect option for BlackRock to increase their exposure to sustainable investing.

Elon Musk made it clear from day one that his vision revolved around electric cars powered by energy harvested from the sun with solar panels.

Mad Money host Jim Cramer believes that Tesla stock is the ideal place for BlackRocks divested oil money to flow into.

Cramer went so far as to call the EV manufacturer Larry Finks ultimate stock.

This is heady praise considering BlackRocks titanic AUM figure.

It doesnt hurt that Larry Fink is already one of the largest owners of TSLA stock, and recently upped his holdings by 5.37% in November last year. Of course, Fink isnt necessarily a fan of Elon Musk, as BlackRock voted to oust the mercurial billionaire from his role as chairman in 2018.

So how much money can flow out of the pipeline and into Tesla stock? A lot.

In 2019, the asset manager had around $90 billion worth of assets in oil, coal, and gas. This is only slightly less than TSLAs entire market cap, highlighting how much capital could be re-deployed at Finks command.

BlackRock has reportedly lost $90 billion investing in fossil fuels over the last decade, so dont be fooled that Larry Fink has a sudden desire to help save the koalas.

Currently riding parabolic arc, Tesla stock is at all-time highs. The run-up appears to have been mostly fueled by a genuinely-historic short squeeze.

Its also possible that word had gotten out on Wall Street about BlackRocks upcoming shift, or even that the $7 trillion behemoth has wisely covertly started re-deploying its cash.

While it isnt clear precisely what has happened in the market, two things are apparent. Tesla stock is the perfect target for Finks push into more sustainable investments, and there is more than enough fossil fuel money on hand to drive an already-elevated TSLA to the moon.

Disclaimer: This article represents the authors opinion and should not be considered investment or trading advice from CCN.com.

This article was edited by Josiah Wilmoth.

Last modified: January 14, 2020 6:56 PM UTC

See the article here:

Why BlackRock May Pump Teslas Stock to the Moon - CCN.com

Production Of Tesla Semi Set To Kick Off In Second Half Of 2020 – InsideEVs

Posted on January 19, 2020 by Danzig

Tesla has the potential to revolutionize the cargo-hauling scene with its upcoming all-electric Semi truck, and it looks like this revolution may start in the second half of this year. This information comes courtesy of a purported leaked email sent by the manufacturer to Semi reservation holders.

The email states that Tesla is still hard at work testing the Semi, both at its Fremont facility, as well as in harsher climates where prototypes are being subjected to cold weather testing and low traction conditions. Regarding the latter, the automaker says the trucks electric powertrain and motor control provides excellent traction, unmatched by conventional diesel trucks.

Initially, Tesla wanted to start Semi production in 2019, but it has been pushed back due to unspecified reasons. Our take is that the company is working on improving the specifications of the vehicle, especially its range - it was initially announced that two versions would go on sale, with ranges of 300 and 500 miles respectively.

Back in 2017, Musk stated that they could already achieve the 500-mile range claim, even without battery tech improvements. He specifically said he expects the final production-spec Semi to exceed 500 miles on a single charge and we have good reason to believe this is one of the reasons the start of production has been pushed back.

18 Photos

Theres also no charging infrastructure for it in place yet - the Semi will have battery packs whose capacity may even exceed 800 kWh, so even charging it at a Supercharger would take too long, and it would detract from the electric trucks cost-effectiveness. Tesla has begun work on its so-called Megacharger, which will utilize a special liquid-cooled connector that is capable of withstanding the higher current transfer rates needed to make the Semi viable.

Back when the Tesla Semi was unveiled, Elon Musk announced that the truck could gain as much as 400 miles of range in just 30 minutes. Based on how big we think the battery pack will be, its clear that the current 150 kW chargers just wouldnt be fast enough.

See more here:

Production Of Tesla Semi Set To Kick Off In Second Half Of 2020 - InsideEVs

Why stem cells could be the medical innovation of the century – World Economic Forum

Posted on January 19, 2020 by Danzig

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Why stem cells could be the medical innovation of the century - World Economic Forum

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital – By MARIA SCANDALE – The SandPaper

Posted on January 19, 2020 by Danzig

Stafford Township, NJ Stem cell therapy is an incredible process for healing damaged tissue, so it seems remarkable that it is availablefor petsright here in Manahawkin. Stafford Veterinary Hospital, at 211 North Main St., began offering the advanced treatment in 2019, under the direction of Michael Pride, medical director at the facility.

There, stem cell therapy is most commonly applied to osteoarthritis, but can also be used in dogs suffering from hip dysplasia and ligament and cartilage injuries, as well as mobility ailments and some chronic inflammatory issues such as inflammatory bowel disease and chronic kidney disease, which is common in cats.

Stem cell therapy is actually the only thing that can help to reverse the process of arthritis, Pride said. Everything else is a Band-Aid.

This process can actually help to rebuild cartilage and really reduce inflammation without the need of using aspirin-type medications, Pride said. Its a newer technology that we can use to avoid chronic use of medications, which might actually be detrimental in the long term for the liver or kidneys.

Stem cell therapy treats the source of the problem by offering the ability to replace damaged cells with new ones, instructs the website staffordvet.com.

Stem cells are powerful healing cells in the pets body that can become other types of cells. For example, in the case of arthritis, stem cells can become new cartilage cells and have natural anti-inflammatory properties, thus reducing pain and increasing mobility.

The stem cells are your primary structural cell for all other cells in the body; they can differentiate into almost any other cell, explained Pride. Were processing it down into that primordial stem cell; were activating it, and were injecting it into where it needs to be, and it just starts taking on the characteristics of the cells around it.

Table-top machines from MediVet Biologics are the first Adipose Stem Cell therapy kits for in-clinic use, a major advancement. Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010.

Pride believes Stafford Veterinary Hospital offers the only such treatment in the immediate area; another is in Egg Harbor Township, Atlantic County.

Were always trying to figure out different ways to help the patient without hurting them, he said while petting a kitten that had been a patient for another type of treatment.

As stem cell therapy is more in the news regarding humans, a pet owners first question might be where the stem cells come from that are used in the process. The answer: from fat tissue of the pet itself, extracted and processed the same day.

As the therapy has been refined in the last decade, it has actually started to become a lot easier, more cost-effective more recently, said Pride, since weve been able to process fat tissue instead of actually getting bone marrow.

Fat tissue actually has a much higher concentration of adult stem cells than bone marrow does, so its less painful for the patient, they heal a lot easier, and we dont have to process it in a different facility.

Everything comes from the animal, and we give it back to the animal. Nothing comes from another animal. We dont have to worry about them rejecting the sample; its their own tissue, and were giving it back to them.

The pet typically goes home the same day after about eight hours. First, X-rays and a consultation with the veterinarian can determine whether the pet is a candidate for the treatment.

A pet owner may not even know that their animal has arthritis.

Cats have a lot of inflammatory issues that they tend to be very good at hiding, said Pride. A lot of people dont realize that they have arthritis. They think, oh, my cats just getting older; hes not jumping as much; hes not as strong; hes just sleeping most of the day, but actually he has arthritis. Its very difficult to diagnose in cats. A lot of times you end up having to do X-rays to find where the arthritic joints happen to be.

An inch-and-a-half incision is the minor surgery that harvests the fat tissue from the belly while the pet is anesthetized. For a cat, about 20 gramsare extracted. For a large dog, about 40 gramsare needed. While the pet is recovering from the incision surgery, the veterinary hospital is processing the sample. When the sample is ready, the pet is sedated because we then have to give them the joint injections. Then we can reverse the sedation, and they go home.

We asked the doctor if the process always works. He gave the example that on average, a dog such as a boxer that was hobbled is now able to walk without seeming like its painful. In an extreme positive case, a dog that had been barely walking might be bouncing all over the place in two months.

It doesnt always work to the extent that we would love it to, but we usually notice that there is a positive effect from it, Pride remarked. Every patient will be different in what they experience.

For the same reason that everyones situation is going to be different, cost of treatment was not given for this story.

It generally takes about 30 to 60 days for relief to show, the veterinarian said, and the animals progress will be monitored.

On average, results last about 18 months to two years before more stem cells might have to be injected. The procedure takes about an hour.

The nice thing is once we collect those stem cells (from the first procedure), we can bank the leftovers they are cryogenically stored at MediVet corporate headquarters in Kentucky and we dont have to go through the initial anesthetic surgery, said Pride.

Stem cell therapy is one of several innovative modalities available at Stafford Veterinary Hospital. Laser therapy, acupuncture and holistic medicine are others. Care for exotic pets is available, as is emergency pet care.

Visit the website staffordvet.com or call 609-597-7571 for more information on general and specialized services, including: vaccinations, microchipping, spayingand neutering, dental care, wellness exams, dermatology, gastrology, oncology, opthalmology, cardiology, soft-tissue surgery, ultrasound, radiography, nutrition, parasite control, boarding, laborand delivery, end-of-life care, and cremation.

Stafford Veterinary Hospital has been in business since 1965, founded by Dr. John Hauge. Today, five highly skilled veterinarians are on staff, and a satellite, Tuckerton Veterinary Clinic, is at 500 North Green St. in Tuckerton.

Pride has been medical director at Stafford Veterinary Hospital since 2008. He attended Rutgers University, then earned his Veterinary of Medicine degree at Oklahoma State University.

The mild-mannered doctor feels a great rewardfrom treating animals that cant speak for themselves when they feel bad.

These guys, theyre always thankful; you can see what they think, he said of treated pets. The turnaround in their attitude, the turnaround in their ability to be more comfortable, you can see it in their faces; you can see it in their actions. You learn to read animals over time.

Its knowing that were helping those who cant help themselves, he added, and you can see it in them; thats the most gratifying.

mariascandale@thesandpaper.net

Read this article:

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper

Stem cell agency indirectly boosted by national industry group – Capitol Weekly

Posted on January 19, 2020 by Danzig

News

by DAVID JENSEN posted 01.13.2020

One of the nations leading regenerative medicine industry groups is touting multi-billion dollar savings that may be achieved with the type of stem cell and gene therapies that are being developed with cash from Californias financially beleaguered stem cell program.

The industry group is the Washington, D.C-based Alliance for Regenerative Medicine (ARM). It is tackling one of the major issues facing development of commercial stem cell therapies sticker shock at their expected prices, running upwards of a $1 million or more.

The ARM study predicted cost savings of as much as $33.6 billion over about a decade in connection with three afflictions: sickle cell disease (SCD),multiple myeloma (MM) andhemophilia A (Hem A).

Without a willingness from health care insurers to cover the costs and provide a pathway to profit, it is unlikely that the biotech industry will embrace production of the therapies.

In a study released Friday, the group said:

Advances in molecular biology and genetics are leading to new treatments for rare diseases that require new ways of assessing value. CGTs (cell and gene therapies) are directed at the underlying cause of a condition and offer durable, potentially curative, or near-curative benefits. These transformative therapies create challenges for current reimbursement frameworks as they (the therapies) require significant upfront costs but are expected to provide a lifetime of benefits. The recurring treatment costs of chronically-managed patients can be greatly reduced and even eliminated with a one-time administration or short course of these novel therapies.

As CGTs arrive on the market, payers need new models for assessing their value. These treatments could potentially end the patients burden of illness, resulting in cost offsets (eliminating or reducing the need for long-term treatment, hospitalizations, and other care) and productivity gains that span a lifetime. Manufacturers incur a high per-patient development cost for these therapies and payers who bear the cost of treatment may not realize the long-term financial benefits due to health plan switching.

The ARM study predicted cost savings of as much as $33.6 billion over about a decade in connection with three afflictions: sickle cell disease (SCD), multiple myeloma (MM) and hemophilia A (Hem A).

The discussion of the costs of stem cell therapies has special resonance in the Golden State where voters are likely to be asked next fall to give $5.5 billion more to its stem cell agency.

Californias stem cell agency was not mentioned in the study, but it has funded research in all three areas. The agency is a member of ARM.

The study, backed by ARM and performed bythe Marwood Group, said, Access to CGTs for even a modest number of patients with MM, SCD, and Hem A each year can reduce overall disease costs by nearly 23% over a 10-year period. The savings from lowering healthcare costs and raising productivity are considerable, approaching $34 billion by 2029. Of the savings, $31 billion are from a reduction in healthcare costs and $3 billion are from productivity gains.

The model used by ARM assumed CGT prices as high as $2 million. The study said, The model has tested more than 180 different prices across the three potential CGTs that ranged from a minimum test price of $150,000 and up to a maximum price test of $2,000,000. The prices entered into the model created 60 different cost savings curves for all three of drugs in this model. Prices were distributed with more than 50% of test prices in the $100,000-$600,000 price per administration range.

The discussion of the costs of stem cell therapies has special resonance in the Golden State where voters are likely to be asked next fall to give $5.5 billion more to its stem cell agency, known formally as theCalifornia Institute for Regenerative Medicine (CIRM).

The agency, funded with $3 billion in 2004, is down to its last $27 million. A new, proposed ballot initiative is focusing hard on affordability of stem cell treatments. The initiative has no specific solutions but stipulates that a new version of CIRM if the ballot measure is approved should devise some ways to come up with answers for insurers who are not likely to warm easily to $1 million therapies.Eds Note: DavidJensen is a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report, where this story first appeared. He has published more than 4,000 items on California stem cell matters in the past 15 years.

Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News – Dagoretti News

Posted on January 19, 2020 by Danzig

Latest Report on the Animal Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study that offers critical insights related to the growth prospects of the Animal Stem Cell Therapy Market during the forecast period 2017 2025. The report takes into account the historical and current market trends to evaluate the top factors that are likely to influence the growth of the market in the upcoming years.

As per the report, the Animal Stem Cell Therapy Market is poised to grow at a CAGR of ~XX% during the assessment period primarily driven by a growing focus on product innovation, a surge in demand for the Animal Stem Cell Therapy in the developed regions, and potential opportunities in the developing regions.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

Essential findings of the report:

The report aims to address the following queries related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

What Sets Us Apart From the Rest?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Original post:

Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News - Dagoretti News

Study: Mutations in stem cells of young donors can be passed to recipients – STAT

Posted on January 19, 2020 by Danzig

Doctors use stem cell transplants to treat patients with certain cancers or blood disorders. And donors, whose blood or bone marrow is used for the procedures, are typically young, for a variety of reasons.

But a pilot study released Wednesday raised the possibility that such donors are also passing along mutations in stem cells that could lead to health problems for some recipients.

The study found that nearly 45% of younger donors had mutations in the transplanted stem cells that could raise the risk of conditions that are sometimes seen in recipients, a higher rate than presumed. Researchers also reported that some of these mutations persisted and proliferated in the recipients bone marrow for at least a year.

What remains unknown is whether those mutations are actually contributing to health problems for recipients.

The study was small, with just 25 donors included and was not large enough and did not last long enough to determine whether people who received cells with these mutations had worse outcomes after a transplant than recipients who got cells without those mutations. Dr. Todd Druley, the senior author of the paper, which was published in the journal Science Translational Medicine, emphasized that patients should continue to receive these stem cells to treat their leukemias or anemias when recommended.

What were trying to say is that now we can provide surveillance before, during, and after a bone marrow transplant so that if theres an increased risk for a particular outcome, treatment for that and surveillance for that can be instituted sooner, said Druley, a pediatric oncologist at Washington University in St. Louis.

Researchers not involved with the study praised its technical prowess, and said it was worth investigating further to see if the transplanted mutations did lead to worse outcomes for recipients projects that Druley and his colleagues have underway. But they agreed it should not yet change clinical practice.

Donors are already screened to make sure they have a clean bill of health and make for a good match for recipients, based on their immune systems. Experts said it would be unrealistic to screen every potential donor for the kinds of mutations Druley and his team found. Those mutations were infrequent, and it wasnt clear they posed health risks to recipients.

We know that younger donors are better than older donors. We know that the better the donor the better the outcomes. We dont know how these ultra-low level mutations affect outcomes at all, said Dr. Corey Cutler, the medical director of the adult stem cell transplantation program at Dana-Farber Cancer Institute.

Hematopoietic stem cells generate blood and immune cells. They are sometimes transplanted into patients with certain blood or immune disorders or cancers whose own cells have been wiped out by chemotherapy, essentially restocking the recipients with healthy cells.

But recipients of these transplants sometimes experience graft versus host disease (when the transplant attacks the recipients tissues), heart or immune conditions, or even secondary cancers. Some experts have suspected these conditions might be caused by mutations in donor stem cells, among other factors. Its in part why they favor younger donors, who are expected to have fewer mutations than older donors. (Donors from 18 to 44 account for 86% of transplants for unrelated patients. Relatives often make for better donors because they are more likely to be matched to recipients based on immune system molecules.)

Most of these mutations are probably benign. But its possible that other mutations not only pose a health risk, but also give their host cells a boost over other cells, helping them proliferate over time. That might mean someone who is 40 could have a bad mutation in one in 5,000 cells, but by the age of 50, it could be in one in 50 cells, Druley explained.

The challenge is detecting those mutations. Standard sequencing technology may pick up mutations if they appear in just a small percentage of cells, but for young donors, it would be like finding the few pebbles in a beach full of sand.

Next-generation sequencing is good if you want to find a mutation thats in 20% of cells youre looking at, or even 5%, Druley said. Were looking at mutations that are one in a thousand, or down to one in ten thousand.

For the new study, Druley and colleagues trained a more powerful tool they call error-corrected sequencing on the cells of the 25 donors, who ranged from 20 to 58 years old. (Fifty-eight would be considered older donors, but the median age of the donors in the study was 26.) They looked for mutations in 80 genes in particular, including genes that, when mutated, are associated with leukemia.

What they found: 11 donors had a collective 19 mutations that were not picked up by standard sequencing technology 16 of which were pathogenic, meaning disease causing.

The researchers also studied the recipients, finding that 14 of the 19 mutations had engrafted, or been taken up by the recipient and started to generate other cells, and were still there a year after the transplant. Thirteen of these mutations were pathogenic.

Researchers said it made sense that younger adults had these types of mutations, even if scientists hadnt previously been able to spot them.

Its known that mutations accumulate over time, said Dr. Ross Levine, a leukemia specialist at Memorial Sloan Kettering Cancer Center, who was not involved in the new study. The question has always been in other scenarios if you can detect these clones at earlier or in different contexts, and if they mean anything.

The new study was not set up to answer that last question.

Thats the next phase of this research, Druley said. Some of these mutations, if theyre going to have an effect, may not have an effect for many, many years. And we had a small population. So we didnt have enough numbers or enough time.

Outside researchers said that if these stem cell mutations do contribute to diseases once transferred to recipients, it might take so long or happen so infrequently that it would be difficult to study. Dana-Farbers Cutler said that, for example, cases of donor-derived leukemia when the recipient develops blood cancer after a transplant occur in less than 1% of transplants from unrelated donors.

If the mutations do increase the likelihood of complications in recipients, then why arent they posing a problem for the donors themselves? That might also be tied to the prevalence of these mutations, the researchers said.

In donors, these mutations might appear in, say, 1% of cells, and there is competition among cells of all different types of genetic variants to multiply. Plus, donors have healthy immune systems that can help suppress bad actors.

But if cells with these mutations make their way into recipients who have had their own cells blasted away with chemotherapy, its a new race. The mutations might give them some advantage to multiply faster than other cells that were transplanted. And as the percentage of cells with these mutations rises, they might be more likely to cause disease.

When you have these mutations in a host, it may take decades for them to expand to the point of causing issues, Levine said. In a recipient, however, its almost like youve reset the playing field.

Continued here:

Study: Mutations in stem cells of young donors can be passed to recipients - STAT

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News – Dagoretti News

Posted on January 19, 2020 by Danzig

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See original here:

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News

The Clinical Trial that MS Patients Have Been Waiting For – Multiple Sclerosis News Today

Posted on January 19, 2020 by Danzig

People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and its enrolling people with MSat several centers in the United States and one in the United Kingdom.

The U.S. has been behind the curve when it comes to approving stem cell treatments for people with MS. Autologous hematopoietic stem cell transplantation (aHSCT) has been available in Mexico and Russia for several years, but isnt widely available in the U.S.

In the procedure, doctors collect a patients blood-forming stem cells, give the patient high-dose chemotherapy to deplete the immune system, and then return the patients own stem cells to rebuild the immune system. The system, hopefully, returns free of cells believed to be involved with MS.

Three years ago, following a promising aHSCT study, Dr. Anthony Fauci was optimistic but cautious. Fauci is the director of the National Institute of Allergy and Infectious Diseases. He said, These extended findings suggest that one-time treatment with HDIT/HCT may be substantially more effective than long-term treatment with the best available medications for people with a certain type of MS. But Fauci emphasized that a larger trial was still necessary. It appears that trial has finally arrived.

The Phase 3 trial, called BEAT-MS (NCT04047628), will put aHSCT head-to-head against the top-line disease-modifying therapies (DMTs) available in the U.S. to treat MS.

It will enroll 156 adults, ages 18 to 55, with a diagnosis of relapsing-remitting MS (RRMS) at 21 sites 20 in the U.S. and one in the U.K. Participants will be randomly assigned to receive either aHSCT or one of the high-efficacy MS treatments currently in use: Ocrevus (ocrelizumab), Lemtrada/Campath (alemtuzumab), Tysabri (natalizumab), or Rituxan (rituximab). The participants, who wont know which treatment theyre receiving, will be followed for six years.

In a news release, investigators said they want to compare how much time elapses between the start of the treatment and an MS relapse. Theyll also compare the newly developing immune systems of the participants who receive aHSCT with the immune systems of those who receive a DMT.

Finally, theyll compare the effects of the two treatment types on other measures of disease activity and severity, their cost-effectiveness in terms of healthcare costs and productivity, and participants quality of life. We hope that BEAT-MS will clarify the best way to treat people with relapsing MS, said Dr. Jeffrey Cohen, the trials leader.

I hope so, too. A study such as this is long overdue. But I think I echo the feelings of many people with MS when I express dismay that were probably still at least six years away from approval of aHSCT in the U.S.

As I wrote three years ago, [S]cientists have been studying stem cell treatments for years and it sure seems as if were still crawling when we should be cruising. Also, why limit this study to people with RRMS? Why not include those with primary and secondary progressive MS? Am I wrong to think that they would benefit from aHSCT as much, if not more, as those with relapsing MS?

What do you think?

Starting this month, Multiple Sclerosis News Today columnist Jennifer Powell and I have begun recording MS news and feature stories in audio format. Jennifers audio reports are available on SoundCloud every Monday, and mine are available every Thursday. Click here to give us a listen.

Youre invited to visit my personal blog at http://www.themswire.com.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

See the article here:

The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today

Muscular dystrophy collaboration aims to correct muscle stem cells’ DNA – Harvard Office of Technology Development

Posted on January 19, 2020 by Danzig

All News

January 13, 2020

We expect that a satellite cell with the corrected DMD gene would quite quickly and continuously propagate the edited gene throughout the muscle tissue, said Prof. Amy Wagers, who leads the research. (Photo credit: Jon Chase/Harvard Staff Photographer.)

Cambridge, Mass. January 13, 2020 Harvard University stem cell researchers led by Amy Wagers, PhD, are embarking on a major study of Duchenne muscular dystrophy (DMD). Supported by research funding from Sarepta Therapeutics, under a multi-year collaboration agreement coordinated by Harvards Office of Technology Development (OTD), the project aims to use in-vivo genome editing, in mouse models of DMD, to fully and precisely restore the function of the dystrophin protein, which is crucial for proper muscular growth and development. Approaches validated by this work may point the way to an eventual therapeutic strategy to reverse DMD in humans.

Duchenne muscular dystrophy is a genetic disease caused by the lack of a protein called dystrophin that normally helps to support the structural integrity of muscle fibers, including those in the heart. Without the dystrophin protein, cells are weaker and degenerate more quickly. Over time, affected individuals boys, typically, as it is a recessive X-linked disorder lose their capacity to move independently.

Its really a devastating disease; it robs young boys of their capacity to be young boys, said Wagers, who is the Forst Family Professor of Stem Cell and Regenerative Biology, Co-Chair of the Department of Stem Cell & Regenerative Biology, and an Executive Committee Member of Harvard Stem Cell Institute. Though it is early days, Im hopeful that through this work we may identify and validate new avenues for therapy to completely rescue the proper expression and function of the dystrophin protein and regenerate healthy muscle tissue.

Researchers worldwide have pursued a variety of promising approaches such as cell and gene therapies, small-molecule therapies, and others to lessen or prevent the disease and improve patients quality of life.

The strategy pursued by the Wagers Lab at Harvard aims to fully correct the genetic template for dystrophin at its source, in the DNA of stem cells (satellite cells) that create and regenerate muscle cells. Combining cutting-edge CRISPR/Cas9 genome editing technologies with a deep knowledge of stem cell science and regenerative biology, this approach if successful might offer a permanent restoration of muscular function.

In skeletal muscle, muscle fibers are terminally post-mitotic, meaning they cannot divide and they cannot reproduce themselves, Wagers explains. If you lose muscle fibers, the only way to produce new muscle is from stem cells, specifically the satellite cells. The satellite cells are self-renewing, self-repairing, and ready to spring into action to create new muscle fibers. So we expect that a satellite cell with the corrected DMD gene would quite quickly and continuously propagate the edited gene throughout the muscle tissue.

At present, research conducted in mice has shown promising results. In June, the Wagers Lab published the results of editing stem cells in vivo, demonstrating that stem cell genes can be edited in living systems, not only in a dish. In that work, Wagers and her team delivered genome editing molecules to the cells using adeno-associated viruses (AAVs). Her lab has also successfully used gene editing in heart, muscle, and satellite cells to partially restore the function of the DMD gene that encodes dystrophin, by chopping out faulty sequences of code that are disrupting the proper reading frame.

The new stem-cell approach pursued in collaboration with Sarepta would build on these achievements and use more precise genome editing approaches, in animal models of DMD, to entirely replace genetic mutations in the DMD gene with correctly encoded sequences. The project will also explore alternate delivery methods and strategies to mitigate immune effects of in vivo genome editing.

This ambitious project will benefit greatly from the resources and insights of a company with deep clinical experience in the development of therapeutics for muscular dystrophy, said Vivian Berlin, Managing Director of Strategic Partnerships at Harvard OTD. Preclinical discoveries by Harvard researchers may open entirely new possibilities for lifesaving treatments in the long run, offering much-needed hope to patients and families in the future. Were grateful to be able to sustain the important momentum already established in Prof. Wagers lab, through this collaboration.

As we work to bring forward new treatments for patients with DMD, Sarepta is excited to support Prof. Wagers and her lab to accelerate the development of a gene editing approach, which has shown significant potential in early studies, said Louise Rodino-Klapac, Sareptas Senior Vice President of Gene Therapy. This multi-year collaboration is part of Sareptas broader commitment to pursuing all therapeutic modalities and advancing our scientific understanding of gene editing in order to maximize the potential of this approach to help patients.

Under the terms of the agreement between Harvard and Sarepta, the company will have the exclusive option to license any arising intellectual property for the purpose of developing products to prevent and treat human disease. As with any research agreement facilitated by OTD, the right of academic and other not-for-profit researchers to use the technology in further scholarly work is preserved.

All News

View original post here:

Muscular dystrophy collaboration aims to correct muscle stem cells' DNA - Harvard Office of Technology Development

Novel form of cell-free therapy revealed by researchers – Drug Target Review

Posted on January 19, 2020 by Danzig

Researchers have developed cytochalasin B-induced membrane vesicles which they suggest could be a new form of cell-free therapy in regenerative medicine.

Work on extracellular microvesicles (ECMVs) derived from human mesenchymal stem cells (MSCs) has revealed a potential new form of cell-free therapy.

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool in regenerative medicine due to their biocompatibility, miniature size, safety and regenerative properties. These can be used to circumvent the limitations of existing cell therapies without losing any effectiveness.

Cell therapies are grafts or implants of living tissue, such as bone marrow transplants, used to replace and regenerate damaged organ tissue. They currently have limited applications, as they work differently dependent on conditions and the environment they are placed into. They can also be rejected by the immune system.

A study at Kazan Federal University, Russia, has investigated cytochalasin B-induced membrane vesicles (CIMVs) which are also derived from MSCs and are very similar to natural ECMVs.

Proteome analysis of human MSCs and CIMVs-MSCs. Venn diagram of identified proteins MSCs and CIMVs-MSCs (A). Distribution of the identified proteins in organelles, percent of unique identified proteins (B) (credit: Kazan Federal University).

The scientists studied and characterised the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines and chemokines; their immunophenotype was also classified.They also found that CIMVs could stimulate angiogenesis in the same way as stem cells.

The team came to the conclusion that human CIMVs-MSCs can be used for cell-free therapy of degenerative diseases. Induction of therapeutic angiogenesis is necessary for the treatment of ischemic tissue damage (eg, ischemic heart disease, hind limb ischemia, diabetic angiopathies and trophic ulcers) and neurodegenerative diseases (eg, multiple sclerosis and Alzheimers disease), as well as therapies for damage of peripheral nerves and spinal cord injury.

The group say they are continuing to research the therapeutic potential for artificial microvesicles for autoimmune diseases.

The study was published in Cells.

See the original post here:

Novel form of cell-free therapy revealed by researchers - Drug Target Review

Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies – BSA bureau

Posted on January 19, 2020 by Danzig

Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products

Japan based Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc. and Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, have announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited iPSC cell lines, for which Adaptimmune has rights to develop and commercialize resulting T-cell therapy products using its proprietary process for generating T cells from stem cells without the use of feeder cell lines.

Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.

Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.

Under the terms of the agreement, Adaptimmune may receive up to $897.5 million in payments, including:

In addition, Adaptimmune will receive research funding of up to $7.5 million per year.

Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Under the terms of the agreement, Astellas may receive up to $552.5 million, including:

In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.

To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.

The impact of this transaction on Astellas financial results in the fiscal year ending March 31, 2020 will be limited.

Read the original post:

Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies - BSA bureau

Out of the lab and into your frying pan: the advance of cultured meat – The Guardian

Posted on January 19, 2020 by Danzig

I am sitting at a kitchen worktop in the airy offices of San Francisco food startup Eat JUST. As a vegetarian, Im in angst about what is being gently turned over for me in the fryer by one of the chefs. Sitting beside me, the companys CEO Josh Tetrick tries to put my moral dilemma into perspective. Youre not my target market, he says. Its people who are eating meat for breakfast, lunch and dinner.

The product in the fryer is JUSTs prototype chicken nugget, which costs about $50 to make. It is manufactured from what the industry calls cultured, cell-based or cultivated meat (though the outside world knows it more commonly as lab-grown meat). Not to be confused with meat that is plant derived, it is produced directly from animal cells with little need to raise and no need to slaughter actual animals. It is a technology with the potential to fundamentally change the world significantly replacing the way meat is produced now with a kinder and less environmentally damaging alternative.

Cultured meat is a colossal market opportunity says Bruce Friedrich, co-founder and executive director of the Good Food Institute (GFI), a nonprofit organisation that promotes cultured meat and plant-based meat. Even a tiny bite of the $1.4tn annual global meat market would be a lot.

No cultured meat products are on the market yet and nor has it been approved in any country but they are expected to begin trickling into high-end restaurants over the next couple of years. A plethora of companies are at various stages of scaling up production and several have done public and private tasting of various prototypes. They are working on everything from chicken to beef to fish and have both humans and pets in their sights.

The GFI estimates that since San Francisco Bay Area-based Memphis Meats the first startup was founded in 2015, a total of 60 enterprises now make up the market with cultured meat as their sole business focus; collectively they have raised nearly $140m in disclosed funding. That comes mostly from venture capitalists but also from agriculture multinationals such as Tyson and Cargill.

Should cultured meat be allowed to be called meat at allif it hasnt been harvested from a whole animal?

JUST, which isnt included in the GFIs figures because it also makes vegan egg and mayonnaise, announced it was pursuing cultured meat in mid-2017, though it does not disclose what proportion of the $220m-plus it has raised in funding it is directing to its cultured meat endeavours. Meanwhile regulators are working on the approvals process and labelling requirements. Tetrick says JUST is ready to release its chicken nuggets in some high-end restaurants in an Asian country as soon as it has the thumbs up from the countrys regulator, with whom it is in dialogue. Chicken is considered easier in part because the vaccine industry has been using avian stem cells to produce vaccines for years: there is existing knowledge to draw on.

Establishing this industry isnt easy, however. While companies work out technicalities, voices raising concerns about the technology and its implications are coalescing. It is also clear there is no agreed position on whether the material itself even counts as meat. Cultured meat is in a process of becoming, sums up Neil Stephens, a sociologist at Brunel University, London, who has been studying the area for over a decade and co-founded the group Cultivate to help build discussion of the technology. It might become a stable category as meat, but its not there yet.

To a certain extent, the science of culturing meat is relatively well understood. The process begins when a cell is taken from an animal and grown up in a lab to permanently establish a culture (called a cell line). The cells can come from a range of sources: biopsies of living animals, pieces of fresh meat, cell banks and even the roots of feathers, which JUST has been experimenting with. Cell lines can either be based on primary cells for example muscle or fat cells or on stem cells. Stem cells have the advantage that with different nutrients, or genetic modifications, they are able to mature into any cell type. There is also no limit to how long stem-cell lines can live, so it is possible to use them indefinitely to produce a product. Once a good cell line for example, one that grows fast and is tasty has been selected, a sample is introduced into a bioreactor, a vat of culture medium where the cells proliferate exponentially and can be harvested. The resulting meat cell mush can be formed into a plethora of unstructured items, from patties to sausages with or without other ingredients added for texture. Conventional meat has a variety of cell types from which it derives its flavour, including both muscle and fat, and the companies are trying to broadly replicate that.

JUST isnt specifying how the cell source for the particular nugget I am about to try was obtained it gets its cells in many ways but I am assured the process didnt involve any slaughter, which is why I think I am on safe ground eating it. For most people, notes Tetrick, it wont matter how the cell is obtained. It is also not disclosing whether it was grown from a primary cell or a stem-cell line (which it doesnt genetically modify). And I dont know the exact type of chicken cells in the final product.

When I do bite into the nugget which I am told is about 70% chicken, on a par with a premium chicken nugget it has a dense texture and a mild, somewhat creamy flavour that reminds me of a pressed chicken sandwich I once bit into by accident. It also contains an amount of JUSTs own mung bean protein isolate for texture along with water, oil, salt, pepper and, this being a nugget, breading.

Yet while establishing cell lines is one thing, scaling them up for mass production at a competitive price is another. The problem is that the culture medium needed for the cells to grow is expensive and animal cells can take time to proliferate. And there is no guarantee that a small operation will work at large scale.

Compounding the challenge is the need to develop good alternatives to foetal bovine serum (FBS). Derived from the blood of cow foetuses, it is often added to culture media where the growth factors it contains work their magic. But its use is a nonstarter for an industry trying to take animals out of the equation and many companies are hard at work producing their own alternatives. All of the companies have pledged that they will not sell products that involve FBS in the production, notes Friedrich.

A further aspiration of the companies is moving beyond mush. Technologies such as 3D printing and edible scaffolds may enable this and there have been early demos. But producing, say, a fillet is much more difficult than ground meat.

There is also the challenge of getting consumers over the yuck factor. Stephens notes that the people prepared to try it tend to be educated, male and young and that it is they who could help normalise it. Tetrick thinks the answer will ultimately come down to making products that are tasty and affordable and, in the early days at least, educating people about the process and the benefits, which he notes would also extend to safer products because faecal contamination would be eliminated, as would antibiotics (sterile conditions would stop bacteria and viruses taking hold, and if they did, any contaminated batches could be discarded).

For a technology with such far-reaching implications for everything from rural livelihoods to human identity, critical public discussion and debate to date have been relatively limited. But that may be changing.

The website Clean Meat Hoax was launched last year by an informal group of 16 animal rights scholars and activists. It rails against cultured meat on the grounds that it still suggests that meat is desirable, and that animals are a resource people can draw on. It contrasts with the more pragmatic position other animal rights groups such as People for the Ethical Treatment of Animals (Peta) have taken in favour of the technology on the grounds that animals lives will be saved. What is incredible to me is how uncritically this technology is being celebrated and I dont think thats an accident we dont want to consider the possibility that we can stop eating animals, says site founder John Sanbonmatsu, a philosopher at Worcester Polytechnic Institute in Massachusetts.

Meanwhile an advertisement in Brussels metro stations designed to undermine cultured meat contrasts a barn of cows surrounded by greenery to a meat lab surrounded by transmission towers. It is the work of the European Livestock Voice campaign set up last year by a number of European farming industry groups to stress the potential social impacts of upending the meat industry.

Other voices, meanwhile, dont reject the technology wholesale but have concerns over certain aspects.

What to make ofall the company founders who would be vegan if they didnt eat their ownproduce?

Michael Hansen is a senior scientist in the advocacy division of the nonprofit organisation Consumer Reports, which compares consumer products. He worries about the potential for bioreactor contamination but also wants more transparency from the companies on their science. How, for example, are they dealing with cells that spontaneously mutate? And what are the implications of the fact that immortal cell lines could, with their uncontrolled growth, be defined as cancer cell lines? He would also like to see data on how end products compare compositionally and nutritionally with the conventional versions. You would think they would put samples out for somebody to test but all we have are assertions, he says.

The environmental campaign group Friends of the Earth (FoE), meanwhile, is keeping an open mind but stresses that the technology must not distract from existing, proven solutions to helping the planet, such as reducing reliance on animal feed produced on cleared ecoregions, cutting down food waste and supporting healthier diets. It also notes that it is extremely energy intensive to produce cultured meat and that the sustainability claims made by the companies will also need proper assessment. (JUSTs facilities are currently powered by electricity from the grid, but it plans to be more energy efficient in the future).

Perhaps more significantly for the companies, there remains the question of whether cultivated meat should be allowed to be called meat at all if it hasnt been harvested from a whole animal. The United States announced last year that cell-cultured livestock and poultry products would be regulated jointly by the Food and Drug Administration and the Department of Agriculture but further detailed requirements along with labelling rules are awaited.

So far, the industry has done a good job of arguing that its products are meat. While debate continues within the cultured meat industry about exactly what adjective to put in front (clean meat was dropped because funders in the conventional meat industry didnt like the dirty connotation it gave conventional meat), the meat is a constant which asserts its claim to be either a subcategory of meat or just meat. I actually think the word meat does more work [than any of the adjectives], says Stephens. And if Tetrick has his way, using any sort of prefix wont be necessary for long. Phones were only called Smartphones at the beginning, he points out. As something normalises you drop it. At the end of the day this thing is going to be called meat.

But others dont want it to be called meat at all.

Steered by the so called barnyard lobby, which represents the meat, livestock and poultry industries, over 30 US states have considered or are considering so-called truth in labelling laws aimed at preventing words such as meat, beef or pork being used to describe cultured meat (the laws often also target plant-based products). So far, laws have been passed in 12 states. Under Louisianas new law, which takes effect later this year, meat would specifically exclude anything that was a cell-cultured food product grown in a laboratory from animal cells. While state laws will be superseded when federal labelling rules for cultured meat come in, it doubtless sends a strong message to regulators as they decide.

Yet, notes Friedrich, whose GFI is challenging various pieces of state legislation in court, the outcomes could be really bizarre if cultivated meat cannot be called meat. Some people have meat allergies Its a consumer safety issue, he says.

If meat were to removed from the name, it would be a blow to an industry that believes that being recognised as meat is the most likely way to change the world. Perhaps it is unsurprising, then, that last year cultured meat companies came together to form their own lobby group.

Meanwhile, whats a vegetarian to do where cultured meat is concerned? And what to make of the many company founders, including Tetrick, who would be vegan if they didnt eat their own products? For the UK Vegetarian Society, there isnt enough information yet to decide whether cultured meat can be considered vegetarian. There are still questions to answer, it says, adding that those questions centre on production, ingredients, provenance and ethics. In contrast, for the UK Vegan Society, it is definitively not a vegan product because the initial cells are taken from animals. We may need a new word for people who eat exclusively cultivated meat, says Friedrich.

Certainly, from what meat is to what it is to be vegetarian or vegan, cultured meat is blowing apart our existing categorisations. Meat cell product, anyone?

Cats and dogs consume more than 25% of the US meat supply. Pet food company Because Animals wants to see those diets replaced with meat grown in the lab. Pet food has a huge environmental footprint, says Shannon Falconer, co-founder and CEO. The company plans to launch a mouse meat cat treat made of 10% mouse cells as its first cultured meat product. It demonstrated a prototype last year. Culturing rabbit meat for dog food is next. It is a more natural diet for them that is more compatible with their digestion, says Falconer.

Wild Earth, a San Francisco Bay Area-based startup, also set out culturing mouse meat for cats but changed course after its market research showed many pet owners were alarmed by the prospect and didnt understand the concept. They thought we were killing mice and putting them into cans, says Ryan Bethencourt, co-founder and CEO. (Jokingly, Bethencourt codenamed the would-be product Jerry, inspired by Tom and Jerry cartoons.) It is now working on growing chicken and fish for dogs and cats instead. The vision is for a premium raw product in the first instance, appealing to those who feed conventional raw meat to their animals.

Bethencourt wonders whether pet food might be a gateway for cultured meat. People have shown greater willingness to be innovative with pet food, he says, citing the popularity of cricket treats for dogs. Pet food isnt so steeped in taste and tradition. The biggest market driver is expected to be pet owners wanting to avoid contaminants such as euthanasia drugs, which can get into pet food in the animal flesh that goes into the ingredients.

But cultured meat is not likely to be approved for pet food ahead of human food pet food regulators take their cues from human-food regulators. Meanwhile the industry has some advantages. Creating texture or perfecting taste is less important. And people are used to pet food being a blend of different ingredients. Percentages of cultured meat also dont have to be as high. Financially its going to be more feasible to be a pet food company, says Falconer.

Read the original:

Out of the lab and into your frying pan: the advance of cultured meat - The Guardian

Botox, medical drips and more offered at NVY Center – SILive.com

Posted on January 19, 2020 by Danzig

STATN ISLAND, N.Y. -- As a Manhattan-based attorney, Chris Cardillo has overseen his share of medical management over the years.

Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices.

So with a wide knowledge of the medical industry, he sought to open a business that would house different physicians, as well as spa services, in a medical spa setting under one roof.

The result is NVY Center, a medical management company that opened in Richmond Valley more than one year ago.

As a Manhattan-based attorney, Chris Cardillo has completed his share of medical management over the years. Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices. (Staten Island Advance/Tracey Porpora)

I became very interested in the concept because I think its the wave of the future, said Cardillo, who has several partners in the business. Almost every medical office has a medical manager. ...When you go to a hospital, like New York University Medical Center, the hospital does all the management for doctors with affiliated practices. What hospitals do for their doctors, we do on a private level.

MEDICAL, SPA SERVICES UNDER ONE ROOF

NVY Center rents a clean, white expansive space to various medical professionals, and aestheticians, who provide spa services.

We are hoping to be a national brand. What we do is solicit doctors to lease space for us and we manage them. That means when a doctor comes in here the only thing the doctor has to worry about is taking care of the patient, said Cardillo. We take care of the billing. They dont have to do any of the paperwork. Everything they need to do their job is here for them already.

Under the NVY Center roof are an array of spa services -- from stem cell therapy and IV drips to facials and aesthetic injections. (Staten Island Advance/Tracey Porpora)

MEDICAL SPA SERVICES

Under the NVY Center roof are also an array of medical spa services, from stem cell therapy and IV drips, to facials and aesthetic injections.

Included in the facilitys design are individual medical offices, rooms where different procedures, such as facials, can take place, and an IV drip chair area. And the facility always has a medical professional on the premises, said Cardillo.

We do everything from anti-hangover to anti-flu drip. ... Soon, well be able to come to your house and do an IV drip, explained Cardillo. We want this to be a one-stop-shop for modern services."

He noted the IV drips often include vitamins and are used for various purposes, including by those people who desire to lose weight.

We have fast-drips that are 15 minutes long, where we can fill you with fluids if youre not feeling good, said Cardillo. Depending on what were trying to treat, we will mix vitamins and other medicines into the IV drip. But the fluid helps no matter what.

He said the company also hosts IV drip and Botox parties.

Other services include Trusculpting," a fat reduction procedure to lose weight, and laser hair removal, said Cardillo.

NVY CENTER AT A GLANCE

Address: 236 Richmond Valley Rd.

Website: http://www.nvycenter.com

Facebook: http://www.facebook.com/nvycenter/

New Businesses in Focus is a weekly column that relates the stories of new Staten Island businesses owners.

If you have a new business on Staten Island, e-mail porpora@siadvance.com.

MORE NEW BUSINESSES IN FOCUS COLUMNS:

FOLLOW TRACEY PORPORA ON FACEBOOK and TWITTER

View original post here:

Botox, medical drips and more offered at NVY Center - SILive.com

Select Page ::